Anna Spreafico

Trials

Studies that name Anna Spreafico as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:55 UTC. Open this list on ClinicalTrials.gov

• N/A
  NCT06630273 · Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics

  Canadian Cancer Trials Group · not yet recruiting · Carcinoma · study chair
• Ph2
  NCT05743777 · PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

  Canadian Cancer Trials Group · withdrawn · Advanced Head and Neck Squamous Cell Carcinoma · study chair
• N/A
  NCT04243720 · Immune Resistance Interrogation Study

  University Health Network, Toronto · recruiting · Cancer, Solid Tumor, Metastatic Cancer · principal investigator
• N/A
  NCT04107311 · Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients

  University Health Network, Toronto · active not recruiting · Solid Tumor · principal investigator
• Ph2
  NCT03839342 · Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

  University Health Network, Toronto · active not recruiting · Solid Tumor · principal investigator
• N/A
  NCT03838601 · Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2

  University Health Network, Toronto · completed · Head and Neck Squamous Cell Carcinoma · principal investigator
• Ph1
  NCT03816358 · Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

  National Cancer Institute (NCI) · active not recruiting · Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8 · principal investigator
• N/A
  NCT03759730 · Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma

  University Health Network, Toronto · completed · Locoregionally-advanced Oropharyngeal Squamous Cell Carcinoma · principal investigator
• Ph2/Ph3
  NCT03686202 · Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients

  University Health Network, Toronto · active not recruiting · All Solid Tumors · principal investigator
• Ph2
  NCT03410615 · Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

  Canadian Cancer Trials Group · active not recruiting · Oropharyngeal Squamous Cell Carcinoma · study chair
• N/A
  NCT02069730 · A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

  University Health Network, Toronto · completed · Salivary Gland Cancer, Metastatic, Advanced · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• North American Star Consortium
  UM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026
  Named on NCT03816358